166 related articles for article (PubMed ID: 17238227)
1. In search of a corrected prescription drug elasticity estimate: a meta-regression approach.
Gemmill MC; Costa-Font J; McGuire A
Health Econ; 2007 Jun; 16(6):627-43. PubMed ID: 17238227
[TBL] [Abstract][Full Text] [Related]
2. Estimating the price elasticity of expenditure for prescription drugs in the presence of non-linear price schedules: an illustration from Quebec, Canada.
Contoyannis P; Hurley J; Grootendorst P; Jeon SH; Tamblyn R
Health Econ; 2005 Sep; 14(9):909-23. PubMed ID: 16127675
[TBL] [Abstract][Full Text] [Related]
3. Gap in drug coverage often causes lapses in adherence to drug regimen, study shows.
Levenson D
Rep Med Guidel Outcomes Res; 2004 Sep; 15(18):9-10, 12. PubMed ID: 15452947
[No Abstract] [Full Text] [Related]
4. Pharmaceutical insurance and the demand for prescription pharmaceuticals in Västerbotten, Sweden.
Rudholm N
Scand J Public Health; 2005; 33(1):50-6. PubMed ID: 15764241
[TBL] [Abstract][Full Text] [Related]
5. The impact of cost sharing of prescription drug expenditures on health care utilization by the elderly: own- and cross-price elasticities.
Li X; Guh D; Lacaille D; Esdaile J; Anis AH
Health Policy; 2007 Aug; 82(3):340-7. PubMed ID: 17134787
[TBL] [Abstract][Full Text] [Related]
6. Controlling prescription drug expenditures: a report of success.
Miller DP; Furberg CD; Small RH; Millman FM; Ambrosius WT; Harshbarger JS; Ohl CA
Am J Manag Care; 2007 Aug; 13(8):473-80. PubMed ID: 17685828
[TBL] [Abstract][Full Text] [Related]
7. Role of health insurance coverage in women's access to prescription medicines.
Ranji UR; Wyn R; Salganicoff A; Yu H
Womens Health Issues; 2007; 17(6):360-6. PubMed ID: 18042485
[TBL] [Abstract][Full Text] [Related]
8. Analysis of a pharmaceutical risk sharing agreement based on the purchaser's total budget.
Zaric GS; O'brien BJ
Health Econ; 2005 Aug; 14(8):793-803. PubMed ID: 15685669
[TBL] [Abstract][Full Text] [Related]
9. A sustainable future?: the role of premium subsidies in Medicare prescription drug plans.
Demchak C
Find Brief; 2007 Jan; 10(2):1-6. PubMed ID: 17302011
[No Abstract] [Full Text] [Related]
10. New estimates of the demand for physical and mental health treatment.
Meyerhoefer CD; Zuvekas SH
Health Econ; 2010 Mar; 19(3):297-315. PubMed ID: 19350688
[TBL] [Abstract][Full Text] [Related]
11. Effects of cost sharing on physician utilization under favourable conditions for supplier-induced demand.
Van de Voorde C; Van Doorslaer E; Schokkaert E
Health Econ; 2001 Jul; 10(5):457-71. PubMed ID: 11466806
[TBL] [Abstract][Full Text] [Related]
12. Structural estimation of a principal-agent model: moral hazard in medical insurance.
Vera-Hernández M
Rand J Econ; 2003; 34(4):670-93. PubMed ID: 15025029
[TBL] [Abstract][Full Text] [Related]
13. On the demand for prescription drugs: heterogeneity in price responses.
Skipper N
Health Econ; 2013 Jul; 22(7):857-69. PubMed ID: 22899231
[TBL] [Abstract][Full Text] [Related]
14. Unraveling the ramifications of recent pharmaceutical industry acquisitions by looking at the past, present and future of PBMs (pharmacy benefit management firms).
Herzfeld JD
Empl Benefits J; 1995 Mar; 20(1):20-3, 30. PubMed ID: 10142515
[No Abstract] [Full Text] [Related]
15. Payments, promotion, and the purple pill.
Ridley DB
Health Econ; 2015 Jan; 24(1):86-103. PubMed ID: 25491652
[TBL] [Abstract][Full Text] [Related]
16. Optimal quality, waits and charges in health insurance.
Gravelle H; Siciliani L
J Health Econ; 2008 May; 27(3):663-74. PubMed ID: 18191254
[TBL] [Abstract][Full Text] [Related]
17. The demand for physician services. Evidence from a natural experiment.
Cockx B; Brasseur C
J Health Econ; 2003 Nov; 22(6):881-913. PubMed ID: 14604552
[TBL] [Abstract][Full Text] [Related]
18. Out-of-pocket costs to users: medicine options for hypertension.
Arredondo A
Am J Hypertens; 2008 May; 21(5):492. PubMed ID: 18437138
[No Abstract] [Full Text] [Related]
19. The economics of drug discovery and the ultimate valuation of pharmacotherapies in the marketplace.
Sollano JA; Kirsch JM; Bala MV; Chambers MG; Harpole LH
Clin Pharmacol Ther; 2008 Aug; 84(2):263-6. PubMed ID: 18547999
[TBL] [Abstract][Full Text] [Related]
20. Formulary tier placement for commonly prescribed branded drugs: benchmarking and creation of a preferred placement index.
Mullins CD; Palumbo FB; Saba M
Am J Manag Care; 2007 Jun; 13(6 Pt 2):377-84. PubMed ID: 17567239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
